Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology
Go back to Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology| REVANCE THERAP (NASDAQ: RVNC) | Delayed: 3.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.65 | 52 Week High | $41.12 | |||
| Open | $3.65 | 52 Week Low | $12.35 | |||
| Day High | $3.65 | P/E | N/A | |||
| Day Low | $3.65 | EPS | $-27.14 | |||
| Volume | 13,230,686 | |||||
